Safety Monitoring Board Recommends Continuation Of EntreMed's MKC-1 Phase 2 Breast Cancer Study

Wed, 24 Jan 2007 02:00 PM EST

... EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today announced a favorable review of MKC-1 safety data by an independent Data Safety Monitoring Board (DSMB). [click link for full article] ...